Probiont Oy is developing a personalized solution for cancer therapy efficacy assessment. The organ-on-a-chip platform is purposed to enable rapid screening of cancer immunotherapeutics, for early identification of effective treatment strategies for individual patients.

 

  • Founding year:
  • 2021
  • Development phase:
  • Prototype
  • Funding stage:
  • Pre-seed
  • Website:
  • Contact person info:
  • benedek.poor(at)probiont.fi
  • Team members:
  • 3